Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 12/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052824 | 0.76 | SMPD1 (0.62) | SMPD1BCL2L1MCL1NR4A2NR1H4 | |
| SCHEMBL7076566 | 0.76 | BCL2L1 (0.55) | SMPD1BCL2L1MCL1NR4A2NR1H4 | |
| SCHEMBL7076349 | 0.76 | BCL2L1 (0.43) | BCL2L1MCL1 | |
| SCHEMBL7045604 | 0.76 | SMPD1 (0.61) | SMPD1BCL2L1MCL1NR4A2NR1H4 | |
| SCHEMBL7076910 | 0.73 | HDAC1 (0.59) | SMPD1BCL2L1MCL1NR1H4 | |
| SCHEMBL7044608 | 0.72 | SMPD1 (0.53) | SMPD1BCL2L1MCL1NR4A2NR1H4 | |
| SCHEMBL7076564 | 0.72 | HDAC1 (0.55) | SMPD1BCL2L1MCL1NR1H4 | |
| SCHEMBL7050679 | 0.71 | ALDH1A1 (0.32) | — | |
| SCHEMBL1608032 | 0.70 | SMPD1 (1.00) | SMPD1GUSBNR4A2NR1H4GPR132 | |
| SCHEMBL7081001 | 0.70 | HDAC1 (0.56) | SMPD1BCL2L1MCL1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | AJINOMOTO CO. INC. (JP) | 2003-08-28 | — | — | US | disclosed |
| US-6555584-B1 | Acetyl-coa carboxylase inhibitors | AJINOMOTO CO., INC. (JP) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162818-A1 | Acylsulfonamide derivative | ACSS2, ACACA, FASN | SMPD1 760/4885BCL2L1 1792/4885MCL1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.